Journal: European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology

Article Title: The ? 2 adrenergic receptor antagonist idazoxan, but not the serotonin-2A receptor antagonist M100907, partially attenuated reward deficits associated with nicotine, but not amphetamine, withdrawal in rats

doi: 10.1016/j.euroneuro.2010.05.003

Figure Lengend Snippet: Diagram of Experiment 5 showing the sequence of chronic concurrent treatment with M100907 and nicotine (A) or amphetamine (B). Arrows indicate osmotic minipump implantation/removal time-points.

Article Snippet: M100907 (commissioned for custom synthesis by ANAWA Trading SA, Zurich, Switzerland) for systemic administration was dissolved in sterile 0.9% saline with 1/3 or 1/4 equivalent HCl 0.1N and injected i.p. in a volume of 2 ml/kg.

Techniques: Sequencing

Journal: European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology

Article Title: The ? 2 adrenergic receptor antagonist idazoxan, but not the serotonin-2A receptor antagonist M100907, partially attenuated reward deficits associated with nicotine, but not amphetamine, withdrawal in rats

doi: 10.1016/j.euroneuro.2010.05.003

Figure Lengend Snippet: Brain reward thresholds after acute administration of idazoxan or M100907 (i.p., 30 min before the ICSS session). Data are expressed as a percentage of baseline thresholds (mean ± SEM). No statistically significant differences were observed between idazoxan- and vehicle-treated rats. M100907 significantly elevated thresholds compared with the vehicle-treated group (* p < 0.05, ** p < 0.01, Newman-Keuls post hoc test).

Article Snippet: M100907 (commissioned for custom synthesis by ANAWA Trading SA, Zurich, Switzerland) for systemic administration was dissolved in sterile 0.9% saline with 1/3 or 1/4 equivalent HCl 0.1N and injected i.p. in a volume of 2 ml/kg.

Techniques:

Journal: European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology

Article Title: The ? 2 adrenergic receptor antagonist idazoxan, but not the serotonin-2A receptor antagonist M100907, partially attenuated reward deficits associated with nicotine, but not amphetamine, withdrawal in rats

doi: 10.1016/j.euroneuro.2010.05.003

Figure Lengend Snippet: The effects of M100907 treatment on brain reward thresholds (A) and somatic signs (B) during spontaneous nicotine withdrawal (mean ± SEM). Data on thresholds are presented as a percentage of baseline thresholds before nicotine/saline exposure. *p < 0.05, **p < 0.01, statistically significant differences between somatic signs of nicotine-exposed rats treated with M100907 or vehicle compared with saline-exposed rats treated with M100907 or vehicle. Abbreviation p1-p6 corresponds to pump days 1-6. @, statistically significant main effect of nicotine withdrawal on thresholds (p < 0.01) independent of M100907 treatment.

Article Snippet: M100907 (commissioned for custom synthesis by ANAWA Trading SA, Zurich, Switzerland) for systemic administration was dissolved in sterile 0.9% saline with 1/3 or 1/4 equivalent HCl 0.1N and injected i.p. in a volume of 2 ml/kg.

Techniques: Saline

Journal: European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology

Article Title: The ? 2 adrenergic receptor antagonist idazoxan, but not the serotonin-2A receptor antagonist M100907, partially attenuated reward deficits associated with nicotine, but not amphetamine, withdrawal in rats

doi: 10.1016/j.euroneuro.2010.05.003

Figure Lengend Snippet: Effects of idazoxan (A) and M100907 (B) treatment on brain reward thresholds during DHβE-precipitated nicotine withdrawal (mean ± SEM). Data on thresholds are presented as percent of the baseline thresholds obtained the day before DHβE-precipitated withdrawal. @, statistically significant main effect of precipitated nicotine withdrawal on thresholds (p < 0.0001) independent of idazoxan or M100907 treatment.

Article Snippet: M100907 (commissioned for custom synthesis by ANAWA Trading SA, Zurich, Switzerland) for systemic administration was dissolved in sterile 0.9% saline with 1/3 or 1/4 equivalent HCl 0.1N and injected i.p. in a volume of 2 ml/kg.

Techniques:

Journal: European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology

Article Title: The ? 2 adrenergic receptor antagonist idazoxan, but not the serotonin-2A receptor antagonist M100907, partially attenuated reward deficits associated with nicotine, but not amphetamine, withdrawal in rats

doi: 10.1016/j.euroneuro.2010.05.003

Figure Lengend Snippet: The effects of idazoxan (A) and M100907 (B) treatment on brain reward thresholds during amphetamine withdrawal (mean ± SEM). No effect of idazoxan or M100907 treatment was observed on brain reward thresholds during amphetamine withdrawal. @, p < 0.0001, significant main effect of amphetamine withdrawal.

Article Snippet: M100907 (commissioned for custom synthesis by ANAWA Trading SA, Zurich, Switzerland) for systemic administration was dissolved in sterile 0.9% saline with 1/3 or 1/4 equivalent HCl 0.1N and injected i.p. in a volume of 2 ml/kg.

Techniques:

Journal: European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology

Article Title: The ? 2 adrenergic receptor antagonist idazoxan, but not the serotonin-2A receptor antagonist M100907, partially attenuated reward deficits associated with nicotine, but not amphetamine, withdrawal in rats

doi: 10.1016/j.euroneuro.2010.05.003

Figure Lengend Snippet: The effects of chronic M100907 treatment on brain reward thresholds under baseline conditions, during concurrent administration with nicotine/amphetamine, and during nicotine/amphetamine withdrawal (mean ± SEM). Arrows indicate osmotic minipump implantation/removal. Abbreviation d2-d27 corresponds to experimental days 2-27. @, p < 0.01 significant main effect of M100907 treatment under baseline conditions and during nicotine/amphetamine withdrawal revealed in ANOVA analyses.

Article Snippet: M100907 (commissioned for custom synthesis by ANAWA Trading SA, Zurich, Switzerland) for systemic administration was dissolved in sterile 0.9% saline with 1/3 or 1/4 equivalent HCl 0.1N and injected i.p. in a volume of 2 ml/kg.

Techniques:

Journal: European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology

Article Title: The ? 2 adrenergic receptor antagonist idazoxan, but not the serotonin-2A receptor antagonist M100907, partially attenuated reward deficits associated with nicotine, but not amphetamine, withdrawal in rats

doi: 10.1016/j.euroneuro.2010.05.003

Figure Lengend Snippet: Total number of somatic signs (± SEM) during nicotine withdrawal and chronic treatment with M100907 (0.5 mg/kg/day, days 23-25). M100907 tended to exacerbate the increases in the number of somatic signs seen in nicotine-withdrawing rats and had no effect on somatic signs of vehicle-withdrawing rats.

Article Snippet: M100907 (commissioned for custom synthesis by ANAWA Trading SA, Zurich, Switzerland) for systemic administration was dissolved in sterile 0.9% saline with 1/3 or 1/4 equivalent HCl 0.1N and injected i.p. in a volume of 2 ml/kg.

Techniques:

Journal: European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology

Article Title: The ? 2 adrenergic receptor antagonist idazoxan, but not the serotonin-2A receptor antagonist M100907, partially attenuated reward deficits associated with nicotine, but not amphetamine, withdrawal in rats

doi: 10.1016/j.euroneuro.2010.05.003

Figure Lengend Snippet: Brain reward thresholds during withdrawal from chronic treatment with M100907 (M, 0.5 mg/kg/day). Data are presented as a percentage of baseline thresholds (mean ± SEM). There were no significant differences between M100907 and vehicle treated rats.

Article Snippet: M100907 (commissioned for custom synthesis by ANAWA Trading SA, Zurich, Switzerland) for systemic administration was dissolved in sterile 0.9% saline with 1/3 or 1/4 equivalent HCl 0.1N and injected i.p. in a volume of 2 ml/kg.

Techniques: